Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.
about
Is DRE essential for the follow up of prostate cancer patients? A prospective audit of 194 patientsEvaluation of a rapid quantitative determination method of PSA concentration with gold immunochromatographic strips.Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.The addition of a sagittal image fusion improves the prostate cancer detection in a sensor-based MRI /ultrasound fusion guided targeted biopsyTestosterone replacement therapy and the risk of prostate cancer. Is there a link?Assessment of a fragment of e-cadherin as a serum biomarker with predictive value for prostate cancer.Genomic signatures associated with the development, progression, and outcome of prostate cancer.Chinese nomogram to predict probability of positive initial prostate biopsy: a study in Taiwan region.A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients.Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination.Prediction of prostate cancer in extended-field biopsies of the prostate.Is a digital rectal examination necessary in the diagnosis and clinical staging of early prostate cancer?Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen.An abnormal digital rectal examination is an independent predictor of Gleason > or =7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men.Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer.Development of a new nomogram for predicting the probability of a positive initial prostate biopsy in Japanese patients with serum PSA levels less than 10 ng/mL.Differences in Postoperative Pathological Outcomes between Prostate Cancers Diagnosed at Initial and Repeat Biopsy.Clinico-pathological Correlation of Digital Rectal Examination Findings Amongst Nigerian Men with Prostatic Diseases: A Prospective Study of 236 Cases.Are repeat prostate biopsies safe? A cohort analysis from the SEARCH databaseProstate cancer diagnosed after repeat biopsies have a favorable pathological outcome but similar recurrence rate.Mesonephric remnants of the prostate: incidence and histologic spectrum.Local property characterization of prostate glands using inhomogeneous modeling based on tumor volume and location analysis.Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection.Does repeat biopsy affect the prognosis of patients with prostate cancer treated with radical prostatectomy? Analysis by the number of cores taken at initial biopsy.Developing a new score system for patients with PSA ranging from 4 to 20 ng/mL to improve the accuracy of PCa detection.Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy
P2860
Q24803992-4AE7064A-E234-4C18-8B23-8BE4D0FDFD09Q35831125-333D8C89-597C-4433-8657-321EF85DCCD6Q35924515-7F777715-69F8-49E5-AA40-9C1AD231F373Q36249431-87D5667F-9F25-4FC3-ABD4-8B1B3A8A48F7Q36310652-3A997220-92C2-433A-9A9E-89A26B3C1832Q36615956-B3572AE8-3BF5-4DEB-82A3-A1CFCFA56344Q37031510-16CCB068-E4FF-4731-9B1F-71009FFBA632Q37370466-FFB8161A-DC00-4E9A-B556-64AE90C2DD38Q37485613-023691C0-5924-4265-850B-DC128F545FB6Q37970913-6C1E028A-5507-4F33-BDD3-8EA5BE7F7D67Q39678203-0CBB3E87-7E07-4087-81C3-28F5FA16F9F9Q39713997-B9462E12-6E4A-4E1B-AA84-D79A643DB63FQ39716047-7A0C7116-DFFE-4B9B-BAE0-81DCA4F561A0Q39777849-05158F62-A82C-4C4E-92E7-027B9FFA2E9CQ39786539-3C2353FB-173A-4FB0-A3F5-3047ECB83202Q39845544-20AA8AFE-6636-4172-86AA-BA3B6277031DQ40061056-4F9AF371-FDDE-4679-A817-C77F08308591Q40136506-4A6C4A35-8439-43B0-8D7A-C08D2433F86BQ41907809-36F3D9DB-8E0D-43A9-9766-B7CA4B731ED5Q41992191-7D20DD73-DA98-4407-ADF8-842007D0B188Q42444662-5F2B6EDA-FBC0-45A1-AC06-7E23D268DCB3Q44122216-BE3691BD-C2DE-4C6E-9BC2-CB64277EA958Q45953794-0AC51503-5DCA-4BF5-868C-6D10E704E883Q53405660-C86CD047-E9AC-410D-A104-1C66259B672EQ54273712-AC8722D0-987E-4BEC-804C-FEF8E488EB39Q57239036-FD82D164-5C4C-431E-88D4-5A71783AA38B
P2860
Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Age, prostate-specific antigen ...... ity of having prostate cancer.
@en
Age, prostate-specific antigen ...... ity of having prostate cancer.
@nl
type
label
Age, prostate-specific antigen ...... ity of having prostate cancer.
@en
Age, prostate-specific antigen ...... ity of having prostate cancer.
@nl
prefLabel
Age, prostate-specific antigen ...... ity of having prostate cancer.
@en
Age, prostate-specific antigen ...... ity of having prostate cancer.
@nl
P2093
P1433
P1476
Age, prostate-specific antigen ...... ity of having prostate cancer.
@en
P2093
P304
P356
10.1016/S0090-4295(01)00980-3
P407
P577
2001-06-01T00:00:00Z